brett wells
Data supports switching to Hospira biosimilar for RA
June 10, 2015Research and Development, Sales and Marketing EULAR, Hospira, Janssen, RA, brett wells, celltrion, inflectra, rome
Findings presented at EULAR this week from the first real-world study in patients with rheumatic diseases supports switching from J&J’s …
Pharma underwrites medicines bill with £207 million
June 8, 2015Manufacturing and Production, Sales and Marketing ABPI, NHS, PPRS, ahsn, brett wells
The Department of Health and the ABPI have confirmed a payment of £207 million from pharma to underwrite growth of …
Shire makes £12 billion move for Actelion
June 8, 2015Sales and Marketing Actelion, Shire, brett wells, nps pharma
Not a week goes by without a big pharma merger story, and now it’s the turn of Dublin-headquartered Shire that …
Google advances health data collection initiative
June 5, 2015Medical Communications, Sales and Marketing Apple, brett wells, google, healthkit, researchkit, studykit
Google is advancing a suite of applications known as ‘Study Kit’ that enable users to collect and share health information …
Astellas spending $760m on autoimmune tie-up
June 4, 2015Sales and Marketing Astellas, anokion, brett wells, kanyos
Astellas Pharma and Anokion are to collaborate and develop new treatments for type 1 diabetes and celiac disease in a deal that could net …
Perrigo buys OTC products from GSK
June 3, 2015Sales and Marketing GSK, GlaxoSmithKline, Mylan, Perrigo, Teva, brett wells
In an all-cash move with no financial details disclosed Perrigo is buying a portfolio of leading over-the-counter products from GlaxoSmithKline. …
Bayer and Gilead expand in manufacturing
June 2, 2015Manufacturing and Production, Sales and Marketing Bayer, Gilead, brett wells, manufacturing
Both Bayer and Gilead are investing heavily into their manufacturing operations with expansion plans being laid down in Indonesia and …
Pfizer breast cancer drug delivers
June 1, 2015Sales and Marketing ASCO, AZ, Faslodex, Pfizer, breast cancer, brett wells
A Phase III study on Pfizer’s treatment Ibrance in combination with hormone therapy has revealed the drug more than doubled …
Sanofi plays host to German chancellor Angela Merkel
May 29, 2015Manufacturing and Production, Medical Communications, Sales and Marketing France, Germany, Sanofi, angela, brett wells, merkel
German Chancellor Dr Angela Merkel met with Sanofi bosses in Frankfurt to discuss antibiotics and open a new manufacturing facility. …
Actavis and Valeant see FDA approval for IBS drugs
May 28, 2015Sales and Marketing Actavis, FDA, IBS, Valeant, brett wells
Both Actavis and Valeant have been shown the green light for their respective irritable bowel syndrome (IBS) treatments from the …
NHS online starting to take shape
May 20, 2015Medical Communications, Sales and Marketing HSCIC, NHS, brett wells, nhs online
In England over 55 million patients can now order repeat prescriptions, book GP appointments and access their medical records online …
AstraZeneca building $285m biologics plant in Sweden
May 19, 2015Manufacturing and Production, Sales and Marketing AstraZeneca, Sweden, Södertälje, brett wells
AstraZeneca is spending around $285 million on a new high-tech facility for manufacturing of biological medicines in Södertälje, Sweden. The …
Boehringer widens IPF drug’s reach
May 18, 2015Sales and Marketing Boehringer, Esbriet, ats, brett wells, nintedanib, ofev
Boehringer Ingelheim has highlighted new data for its idiopathic pulmonary fibrosis (IPF) treatment Ofev in a Phase II study on …
London hospital pilots Apple watch app in chemotherapy
May 15, 2015Medical Communications, Sales and Marketing Apple, King’s College Hospital, brett wells, chemo, medopad, watch, wearables
King’s College Hospital in London is piloting a scheme whereby cancer patients moving through chemotherapy treatments are given an Apple …
Pharma accused of hiding behind regulation and undermining NICE
April 29, 2015Medical Communications, Sales and Marketing NHS, NICE, Royal Society of Medicine, UK, brett wells, health, pharma
University of York health economists have argued that pharma regulation is not evidence-based, lacks accountability and undermines NICE. Writing in …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
